| NCT06056791 | Study of INKmune in Patients With mCRPC (CaRe Prostate) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2023-11-30 | 2025-11-30 | 2025-08-04 |
| NCT05321498 | Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation | WITHDRAWN | PHASE2 | 2023-06 | 2023-10-26 | 2023-10-26 |
| NCT05522387 | An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-02-21 | 2024-12-31 | 2024-06-05 |
| NCT05318976 | A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation | COMPLETED | PHASE2 | 2022-02-28 | 2025-05-12 | 2025-05-12 |
| NCT04370236 | INB03 for the Treatment of Pulmonary Complications From COVID-19 | TERMINATED | PHASE2, PHASE3 | 2020-10-21 | 2021-11-18 | 2021-10-13 |
| NCT05933070 | A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML | TERMINATED | PHASE1 | 2020-06-15 | 2024-04-26 | 2024-03-28 |
| NCT03943264 | A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's | COMPLETED | PHASE1 | 2019-11-20 | 2021-09-01 | 2021-06-30 |